ZD6474 + Placebo + Docetaxel
Phase 2Completed 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Non-Small Cell Lung Cancer (NSCLC, Locally Advanced or Metastatic, Second-line
Conditions
Non-Small Cell Lung Cancer (NSCLC, Locally Advanced or Metastatic, Second-line
Trial Timeline
Oct 1, 2002 → Sep 1, 2006
NCT ID
NCT00047840About ZD6474 + Placebo + Docetaxel
ZD6474 + Placebo + Docetaxel is a phase 2 stage product being developed by Sanofi for Non-Small Cell Lung Cancer (NSCLC, Locally Advanced or Metastatic, Second-line. The current trial status is completed. This product is registered under clinical trial identifier NCT00047840. Target conditions include Non-Small Cell Lung Cancer (NSCLC, Locally Advanced or Metastatic, Second-line.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00047840 | Phase 2 | Completed |
Competing Products
20 competing products in Non-Small Cell Lung Cancer (NSCLC, Locally Advanced or Metastatic, Second-line